PS-341 and PS-341 + EPOCH Chemotherapy and Molecular Profiling in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

Trial Profile

PS-341 and PS-341 + EPOCH Chemotherapy and Molecular Profiling in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2012

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
    • 27 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
    • 05 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top